4-(2-ethyl-piperidin-1-yl)-2-trifluoromethyl-benzonitrile | 869643-10-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(2-ethyl-piperidin-1-yl)-2-trifluoromethyl-benzonitrile
• 英文别名: 4-(2-ethylpiperidin-1-yl)-2-(trifluoromethyl)benzonitrile
• CAS: 869643-10-7
• 化学式: C₁₅H₁₇F₃N₂
• 分子量: 282.309
• InChiKey: FROZJVLDDDEYSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-氟-2-(三氟甲基)苯甲腈 、 2-乙基哌啶 生成 4-(2-ethyl-piperidin-1-yl)-2-trifluoromethyl-benzonitrile
  参考文献：
  名称：

  Benzonitrile Derivatives to Treat Musculoskeletal Frailty

  摘要：

  本发明涉及新颖的氨基取代苯腈衍生物以及含有这些新颖的氨基取代苯腈衍生物的制药组合物。本发明还涉及使用氨基取代苯腈衍生物的治疗方法，以预防和/或恢复肌肉质量和力量的年龄相关下降，治疗消耗性疾病，治疗低骨量状况，增加肌肉质量，增加瘦体重，减少脂肪体重，并治疗哺乳动物，包括人类的骨折和肌肉损伤。

  公开号：

  US20080045504A1

文献信息

• [EN] BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY<br/>[FR] DERIVES DE BENZONITRILE DESTINES AU TRAITEMENT DE LA FRAGILITE MUSCULO-SQUELETTIQUE
  申请人：PFIZER PROD INC

  公开号：WO2005108351A1

  公开（公告）日：2005-11-17

  This invention relates to novel amino substituted benzonitrile derivatives and to pharmaceutical compositions containing the novel amino substituted benzonitrile derivatives. This invention also relates to methods of treatment using amino substituted benzonitrile derivatives to prevent and/or restore age-related decline in muscle mass and strength, treat a wasting disease, treat a condition that prevents with low bone mass, increase muscle mass, increase lean body mass, decrease fat body mass, and treat bone fracture and muscle damage in mammals, including humans.

  本发明涉及新型氨基取代苯甘脂衍生物以及含有该新型氨基取代苯甘脂衍生物的药物组合物。本发明还涉及使用氨基取代苯甘脂衍生物预防和/或恢复与年龄相关的肌肉量和力量下降的治疗方法，治疗消耗性疾病，治疗导致骨量减少的疾病，增加肌肉量，增加瘦体重，减少脂肪体重，并治疗哺乳动物，包括人类的骨折和肌肉损伤。
• [EN] ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS<br/>[FR] COMPOSÉS CIBLANT DES RÉCEPTEURS HORMONAUX NUCLÉAIRES ANTICANCÉREUX
  申请人：NUVATION BIO INC

  公开号：WO2022204184A1

  公开（公告）日：2022-09-29

  The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

  该披露涉及从核类固醇受体结合物中衍生出的抗癌化合物，包括含有相同化合物的产品，以及它们的使用和制备方法。
• BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY
  申请人：Pfizer Products Incorporated

  公开号：EP1747193A1

  公开（公告）日：2007-01-31
• ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS
  申请人：Nuvation Bio Inc.

  公开号：US20200360523A1

  公开（公告）日：2020-11-19

  The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
• [EN] THERAPEUTIC COMBINATIONS COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND A SELECTIVE ANDROGEN RECEPTOR MODULATOR<br/>[FR] COMBINAISONS THERAPEUTIQUES COMPRENANT UN MODULATEUR SELECTIF DU RECEPTEUR D'OESTROGENES ET UN MODULATEUR SELECTIF DU RECEPTEUR D'ANDROGENES
  申请人：PFIZER PROD INC

  公开号：WO2006024931A2

  公开（公告）日：2006-03-09

  This invention relates to a pharmaceutical combination of a selective estrogen receptor modulator (SERM) and a selective androgen receptor modulator (SARM). Particularly, this invention relates to a pharmaceutical composition comprising cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8­tetrahydronapthalene-2-ol, or a pharmaceutically acceptable salt thereof; and a selective androgen receptor modulator. This invention also relates to methods of treatment using the pharmaceutical composition comprising cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronapthalene­2-ol, or a pharmaceutically acceptable salt thereof; and a selective androgen receptor modulator. Particularly, this invention is directed to methods to prevent and/or restore age-related decline in muscle mass and strength, treat a wasting disease, treat a condition that prevents with low bone mass, increase muscle mass, increase lean body mass, decrease fat body mass, treat bone fracture and muscle damage and treat female sexual dysfunction in mammals, including humans.